Inactive

Federal Business Opportunities (FBO) SOURCES SOUGHT NOTICE Solicitation Number: 75N95021Q00335 Title: pMLV-SARS-CoV-2-Luciferase pseudovirus particle to support SARS-CoV-2 research Classification Code... Federal Business Opportunities (FBO) SOURCES SOUGHT NOTICE Solicitation Number: 75N95021Q00335 Title: pMLV-SARS-CoV-2-Luciferase pseudovirus particle to support SARS-CoV-2 research Classification Code: 6640 NAICS Code: 541714 - Research and Development in Biotechnology (Except Nanobiotechnology) Dollars or Number of Employees: 1,000 employees Description: The purpose of this requisition is to procure pMLV-SARS-CoV-2-Luciferase pseudovirus particle (10X concentrated) for SARS-CoV-2 virus testing to support SARS-CoV-2 research for DPI_SARS-CoV-2_Variant Trace Project through the Therapeutic Development Branch (TDB) in Support of COVID-19 Research. Background: This effort is in response to the Covid-19 pandemic and the effort to continue research on this virus. The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), whose mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Therapeutic Development Branch (TBD) within the National Center for Advancing Translational Sciences (NCATS) Division of Preclinical Innovation (DPI) is furthing their research of SAS-CoV-2. Synthetic viral particles are safer surrogates of native viruses and acquire the tropism and host entry pathway characteristics governed by the heterologous envelope glycoprotein used. They have proven to be very useful tools used in research with many applications, such as enabling the study of entry pathways of enveloped viruses and to generate effective gene-delivery vectors. The basis for their generation lies in the capacity of some viruses, such as murine leukemia virus (MLV), to incorporate envelope glycoproteins of other viruses into a pseudotyped virus particle. These can be engineered to contain reporter genes such as luciferase, enabling quantification of virus entry events upon pseudotyped particle infection with susceptible cells. Therapeutic Development Branch (TDB) proposes to purchase pMLV-SARS-CoV-2-Luciferase pseudovirus particle (10X concentrated) for SARS-CoV-2 virus testing to support SARS-CoV-2 research for DPI_SARS-CoV-2_Variant Trace Project. Purpose and Objectives: The purpose of this procurement is to acquire pMLV-SARS-CoV-2-Luciferase pseudovirus particle (10X concentrated) for SARS-CoV-2 virus testing to support SARS-CoV-2 research for DPI_SARS-CoV-2_Variant Trace Project through the Therapeutic Development Branch (TDB) in Support of COVID-19 Research. Overall, this project will support ongoing work for small molecule and combination screening, in silico virtual screening, nanobody/antibody design and optimization that are part of NCATS’s ongoing work to support the pandemic response. In addition, we are performing in vitro assays to support ACTIV Trace’s efforts to characterize the response of variant SARS-CoV2 viruses to current vaccine and therapeutic interventions. Project requirements: This purchase is for quantity 60(ml) of pMLV-SARS-CoV-2-Luciferase puedovirus particle (10X concentrated) Salient characteristics The characteristics at the minimum shall meet the following requirements: -pseudotyped particles generated using the murine leukemia virus (MLV) pseudotyping system that present SARS-CoV-2 spike protein on the bilayer surface. - The spike proteins could either be delete C-terminal tail, or full length, for a range of spike variants. - The pseudotyped particles should encapsulate firefly luciferase reporter RNA and allow expression of the luciferase RNA reporter through a retroviral system in host cells. - corresponding vg/ml qRT-PCR measurements for each batch of pseudotyped particles we receive - PPs should be concentrated to 10x of what is produced in HEK293 production cells. Anticipated period of performance: Anticipated to be delivered approximately 3-4 days ARO Place of Delivery: The place of delivery shall be: 9800 Medical Center Dr Bldg C Rockville, MD 20850 Other important considerations: Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the work mentioned above. Capability statement /information sought. Respondents must provide clear and convincing documentation of their capability of providing the services specified in this notice. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current in-house capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Nick Niefeld, Contract Specialist at e-mail address nick.niefeld@nih.gov. The response must be received on or before August 10, 2021, at 9 am Eastern Time. “Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).”